Expert Topics
Selected Expert Topics in Molecular Pathology and Precision Oncology
This page lists selected topics that are frequently addressed in consulting projects, expert interviews, and discovery discussions. The emphasis is on molecular pathology, precision oncology, biomarkers, reimbursement, and market access for oncology diagnostics in Germany and Europe.
Selected keywords and consulting topics:
- molecular pathology consulting
- oncology biomarker strategy
- liquid biopsy diagnostics
- minimal residual disease (MRD) testing
- ctDNA monitoring
- tumor mutational burden (TMB)
- homologous recombination deficiency (HRD)
- ESR1 mutations
- PD-L1 testing
- HER2 diagnostics
- NGS panel design
- reimbursement molecular diagnostics Germany
- EBM molecular diagnostics
- GOÄ molecular pathology
- DRG implementation molecular diagnostics
- precision oncology programs
- companion diagnostics strategy
Expert Interviews
Expert interviews and consulting discussions can be provided on topics including molecular pathology, oncology biomarkers, next-generation sequencing, liquid biopsy, and minimal residual disease (MRD) detection in solid tumors.
Expert interviews are frequently conducted for:
- pharmaceutical companies
- biotechnology companies
- diagnostics developers
- healthcare investors
- market research firms
- expert networks
Expert interviews can be conducted in English, German, and Dutch.
Molecular Pathology & Precision Oncology
- Molecular pathology consulting for oncology programs
- Precision oncology consulting and tumor board workflows
- Design of integrated pathology workflows for genomic profiling
- Interpretation of complex genomic reports in solid tumors
- Integration of molecular results into clinical decision pathways
NGS, WGS, WES & Panels
- Next-generation sequencing oncology assay selection
- NGS panel design for solid tumors and hematology
- Whole genome sequencing (WGS) and whole exome sequencing (WES) in translational projects
- Comparing targeted NGS vs. WGS/WES for clinical questions
- Quality, coverage, and reporting standards for genomic diagnostics
Liquid Biopsy & MRD
- Liquid biopsy diagnostics and ctDNA testing strategies
- Analytical and clinical aspects of ctDNA assays
- MRD in solid tumors and tumor-informed MRD assays
- Use of MRD readouts in clinical trials and routine care
- Positioning of liquid biopsy in existing pathology workflows
Biomarkers & IHC
- TMB biomarker and HRD biomarker implementation in oncology
- ESR1 mutation testing and monitoring in breast cancer
- PD-L1 testing and reporting standards
- HER2 diagnostics, including HER2-low and discordant cases
- MTAP biomarker strategies and co-deletion patterns
- Immunohistochemistry biomarkers and multiplex IHC concepts
Genomic Profiling & Workflows
- Genomic profiling strategies for early- and late-line oncology
- Turnaround time and sample logistics in molecular pathology
- Pathology workflows for reflex testing and triage
- Data interpretation and variant classification processes
- Reporting formats and communication with clinical teams
Reimbursement & Market Access
- Reimbursement pathways for molecular diagnostics in Germany
- EBM reimbursement molecular diagnostics and coding options
- GOÄ molecular pathology billing in private care
- IV contracts Germany and selective contracting models
- Oncology diagnostics reimbursement Europe across key markets
- Market access molecular diagnostics and adoption barriers